vs
Side-by-side financial comparison of Las Vegas Sands (LVS) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.
Las Vegas Sands is the larger business by last-quarter revenue ($3.6B vs $3.0B, roughly 1.2× Vertex Pharmaceuticals). Vertex Pharmaceuticals runs the higher net margin — 34.5% vs 17.9%, a 16.7% gap on every dollar of revenue. On growth, Las Vegas Sands posted the faster year-over-year revenue change (25.3% vs 7.8%). Over the past eight quarters, Las Vegas Sands's revenue compounded faster (13.9% CAGR vs 6.3%).
Las Vegas Sands Corp. is an American casino and resort company with corporate headquarters in Las Vegas, Nevada. It was founded by Sheldon G. Adelson and his partners out of the Sands Hotel and Casino on the Las Vegas Strip. The Sands was demolished and redeveloped as The Venetian, opening in 1999. An adjacent resort, The Palazzo, opened in 2007. Both resorts were sold in 2022.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
LVS vs VRTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.6B | $3.0B |
| Net Profit | $641.0M | $1.0B |
| Gross Margin | — | 86.8% |
| Operating Margin | 25.2% | 38.1% |
| Net Margin | 17.9% | 34.5% |
| Revenue YoY | 25.3% | 7.8% |
| Net Profit YoY | 57.1% | 59.6% |
| EPS (diluted) | $0.85 | $4.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.6B | $3.0B | ||
| Q4 25 | $3.6B | $3.2B | ||
| Q3 25 | $3.3B | $3.1B | ||
| Q2 25 | $3.2B | $3.0B | ||
| Q1 25 | $2.9B | $2.8B | ||
| Q4 24 | $2.9B | $2.9B | ||
| Q3 24 | $2.7B | $2.8B | ||
| Q2 24 | $2.8B | $2.6B |
| Q1 26 | $641.0M | $1.0B | ||
| Q4 25 | $395.0M | $1.2B | ||
| Q3 25 | $419.0M | $1.1B | ||
| Q2 25 | $461.0M | $1.0B | ||
| Q1 25 | $352.0M | $646.3M | ||
| Q4 24 | $324.0M | $913.0M | ||
| Q3 24 | $275.0M | $1.0B | ||
| Q2 24 | $353.0M | $-3.6B |
| Q1 26 | — | 86.8% | ||
| Q4 25 | — | 85.4% | ||
| Q3 25 | — | 86.5% | ||
| Q2 25 | — | 86.3% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 85.5% | ||
| Q3 24 | — | 85.8% | ||
| Q2 24 | — | 85.9% |
| Q1 26 | 25.2% | 38.1% | ||
| Q4 25 | 19.4% | 37.8% | ||
| Q3 25 | 21.6% | 38.6% | ||
| Q2 25 | 24.7% | 38.8% | ||
| Q1 25 | 21.3% | 22.7% | ||
| Q4 24 | 20.4% | 35.2% | ||
| Q3 24 | 18.8% | 40.3% | ||
| Q2 24 | 21.4% | -132.9% |
| Q1 26 | 17.9% | 34.5% | ||
| Q4 25 | 10.8% | 37.3% | ||
| Q3 25 | 12.6% | 35.2% | ||
| Q2 25 | 14.5% | 34.8% | ||
| Q1 25 | 12.3% | 23.3% | ||
| Q4 24 | 11.2% | 31.4% | ||
| Q3 24 | 10.3% | 37.7% | ||
| Q2 24 | 12.8% | -135.8% |
| Q1 26 | $0.85 | $4.02 | ||
| Q4 25 | $0.59 | $4.64 | ||
| Q3 25 | $0.61 | $4.20 | ||
| Q2 25 | $0.66 | $3.99 | ||
| Q1 25 | $0.49 | $2.49 | ||
| Q4 24 | $0.44 | $3.62 | ||
| Q3 24 | $0.38 | $4.01 | ||
| Q2 24 | $0.48 | $-13.92 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $19.4B |
| Total Assets | — | $26.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.8B | $6.6B | ||
| Q3 25 | $3.4B | $6.3B | ||
| Q2 25 | $3.5B | $6.4B | ||
| Q1 25 | $3.0B | $6.2B | ||
| Q4 24 | $3.6B | $6.1B | ||
| Q3 24 | $4.2B | $6.5B | ||
| Q2 24 | $4.7B | $5.8B |
| Q1 26 | — | — | ||
| Q4 25 | $14.7B | — | ||
| Q3 25 | $13.9B | — | ||
| Q2 25 | $14.9B | — | ||
| Q1 25 | $10.9B | — | ||
| Q4 24 | $10.6B | — | ||
| Q3 24 | $11.3B | — | ||
| Q2 24 | $12.8B | — |
| Q1 26 | — | $19.4B | ||
| Q4 25 | $1.6B | $18.7B | ||
| Q3 25 | $1.6B | $17.3B | ||
| Q2 25 | $2.0B | $17.2B | ||
| Q1 25 | $2.7B | $16.5B | ||
| Q4 24 | $2.9B | $16.4B | ||
| Q3 24 | $3.4B | $15.6B | ||
| Q2 24 | $3.8B | $14.8B |
| Q1 26 | — | $26.5B | ||
| Q4 25 | $21.9B | $25.6B | ||
| Q3 25 | $21.5B | $24.9B | ||
| Q2 25 | $21.9B | $24.0B | ||
| Q1 25 | $21.2B | $22.9B | ||
| Q4 24 | $20.7B | $22.5B | ||
| Q3 24 | $21.4B | $22.2B | ||
| Q2 24 | $21.1B | $20.1B |
| Q1 26 | — | — | ||
| Q4 25 | 9.22× | — | ||
| Q3 25 | 8.82× | — | ||
| Q2 25 | 7.48× | — | ||
| Q1 25 | 4.02× | — | ||
| Q4 24 | 3.67× | — | ||
| Q3 24 | 3.29× | — | ||
| Q2 24 | 3.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LVS
| Casino | $2.7B | 76% |
| Rooms | $377.0M | 11% |
| Mall | $204.0M | 6% |
| Food and beverage | $176.0M | 5% |
| Convention, retail and other | $89.0M | 2% |
VRTX
| TRIKAFTA/KAFTRIO | $2.4B | 79% |
| ALYFTREK | $424.4M | 14% |
| Other | $135.9M | 5% |
| CASGEVY | $42.9M | 1% |
| Vertex recorded | $29.0M | 1% |
